Skye also reported changes in waist circumference, a key secondary endpoint. Nimacimab plus semaglutide showed a least-means squared (SE) change of -11.26cm (1.16cm) in waist circumference versus ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ...
At top leadership's direction, UT faculty crafted a statement on academic integrity, saying colleges must create a culture of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback